Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?

Biomedicines · 2022 · PMC8869570 · PMID 35203527

Europe PMC DOI

hedged sentence

0.0579

closest p · 1.2× alpha

0.0579

boldest claim

The sentences

did not reach statistical significancep = 0.0579so close (0.05 < p ≤ 0.1)

A more significant skin improvement was seen after 48 weeks with Tocilizumab, but this still did not reach statistical significance (mRSS decrease with 6.33 for Tocilizumab vs. 2.77 for placebo, p = 0.0579).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.